Shareholding disclosure

BB Biotech AG

Declared position

Threshold

Fell below threshold

Timeline

Published

20.04.2013

Transaction

16.04.2013

Transfer date

19.04.2013

Voting rights breakdown

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAD4J00010

Beneficial owner

BB Biotech AG

Declared address

BB Biotech AG, 8200 Schaffhausen

100%-Tochtergesellschaft von BB Biotech AG

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

BB Biotech AG

Actelion Ltd20.04.2013TAD4J00010

Disclosure summary

BB Biotech AG disclosed a holding in Actelion Ltd that fell below the publication threshold, published by SIX Exchange Regulation on 20.04.2013, at 3% of voting rights. Notice category: Single shareholder.

Disclosed position

Below threshold

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

BB Biotech AG disclosed a holding in Actelion Ltd, published on 20.04.2013.

Publication date20.04.2013

Transaction date16.04.2013

Transfer date19.04.2013

Issuing companyActelion Ltd

Beneficial ownerBB Biotech AG

Declared addressBB Biotech AG, 8200 Schaffhausen

CategorySingle shareholder

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

ExchangeXSWX

Notification IDTAD4J00010

Commercial register

CHE-102.169.627

Registered

Zefix record

Conditions

100%-Tochtergesellschaft von BB Biotech AG

Source: SIX Exchange Regulation · Publication date: 20.04.2013

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open